In this Patient Power video - Dr. Brown is very clear about the advantages of Zanubrutinib over Ibrutinib - especially for 17p and patients with heart risks.
patientpower.info/chronic-l...?
Watch as Jennifer Brown, MD, PhD, Director, CLL Center, Dana Farber, updates our chronic lymphocytic leukemia (CLL) patients on the latest from the 2022 American Society of Hematology (ASH) Annual Meeting, including the results of the ALPINE study and the new BTK inhibitors.
-
Len